Drug intelligence / Profile preview

celecoxib + docetaxel + irinotecan

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This combination involves **celecoxib**, a selective cyclooxygenase-2 (COX-2) inhibitor; **docetaxel**, a taxane chemotherapy drug; and **irinotecan**, a topoisomerase I inhibitor. The combination was studied for treating advanced solid tumors but was not recommended due to its side effect profile and lack of enhanced efficacy[1][3].

Targets

TOP1 (DNA Topoisomerase I)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)Microtubule

Beyond the preview

Go deeper on celecoxib + docetaxel + irinotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on celecoxib + docetaxel + irinotecan.

Explore the full profile